Revenue (Tables)

6 Months Ended

Jun. 30, 2022

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We have revised prior periods to conform to current year presentation:

	Three Months Ended June 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	338	$	221	$	560	$	316	$	235	$	551
Urology and Pelvic Health	320		130		450		285		112		397
Neuromodulation	186		53		239		194		53		247
MedSurg	844		404		1,248		794		400		1,195
Interventional Cardiology Therapies	192		382		574		206		369		574
Watchman	225		25		250		192		24		216
Cardiac Rhythm Management	342		199		541		314		210		524
Electrophysiology	73		79		152		34		62		95
Cardiology	832		685		1,517		746		664		1,410
Peripheral Interventions	257		221		478		260		213		473
Cardiovascular	1,089		906		1,996		1,005		877		1,883
Total Net Sales	$	1,933	$	1,311	$	3,244	$	1,800	$	1,277	$	3,077

	Six Months Ended June 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	650	$	441	$	1,091	$	596	$	454	$	1,050
Urology and Pelvic Health	606		257		863		542		216		758
Neuromodulation	346		101		448		345		99		444
MedSurg	1,602		799		2,402		1,483		769		2,252
Interventional Cardiology Therapies	378		740		1,118		400		699		1,100
Watchman	428		48		476		341		45		386
Cardiac Rhythm Management	667		394		1,061		590		403		993
Electrophysiology	123		147		270		64		115		179
Cardiology	1,596		1,329		2,925		1,395		1,263		2,658
Peripheral Interventions	513		430		944		498		407		906
Cardiovascular	2,109		1,760		3,868		1,893		1,670		3,564
Specialty Pharmaceuticals	—		—		—		10		4		13
Total Net Sales	$	3,711	$	2,559	$	6,270	$	3,386	$	2,443	$	5,829

Refer to Note K- Segment Reporting for information on our reportable segments.

	Three Months Ended June 30,				Six Months Ended June 30,
Regions	2022		2021		2022		2021
U.S.	$	1,933	$	1,800	$	3,711	$	3,376
Europe, Middle East and Africa	660		662		1,284		1,266
Asia-Pacific	530		520		1,047		994
Latin America and Canada	120		95		228		180
Medical Devices	3,244		3,077		6,270		5,816
U.S.	—		—		—		10
International	—		—		—		4
Specialty Pharmaceuticals	—		—		—		13
Total Net Sales	$	3,244	$	3,077	$	6,270	$	5,829
Emerging Markets(1)	$	427	$	359	$	817	$	676

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam.